Sylvie Rapior

Prof. Sylvie Rapior

University of Montpellier, Montpellier, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Fungal Diversity
Verified
Journal Article
Open access
PDF file
KHKevin D. Hyde
Kevin D. Hyde
JXJian-Chu Xu
Jian-Chu Xu
SRSylvie Rapior
Sylvie Rapior
RJRajesh Jeewon
Rajesh Jeewon
SLSaisamorn Lumyong
Saisamorn Lumyong
Marc StadlerMarc Stadler
Marc Stadler
Fungi are an understudied, biotechnologically valuable group of organisms. Due to the immense range of habitats that fungi inhabit, and the consequent need to compete against a diverse array of other fungi, bacteria, and animals, fungi have developed numerous survival mechanisms. The unique attributes of fungi thus herald great promise for their application in biotechnology and industry. Moreover, fungi can be grown with relative ease, making production at scale viable. The search for fungal biodiversity, and the construction of a living fungi collection, both have incredible economic potential in locating organisms with novel industrial uses that will lead to novel products. This manuscript reviews fifty ways in which fungi can potentially be utilized as biotechnology. We provide notes and examples for each potential exploitation and give examples from our own work and the work of other notable researchers. We also provide a flow chart that can be used to convince funding bodies of the importance of fungi for biotechnological research and as potential products. Fungi have provided the world with penicillin, lovastatin, and other globally significant medicines, and they remain an untapped resource with enormous industrial potential.

1 January 2002 in Journal of Toxicology: Clinical Toxicology
Verified
Journal Article
Closed access
FEFrançoise Enjalbert
Françoise Enjalbert
SRSylvie Rapior
Sylvie Rapior
JNJanine Nouguier-Soulé
Janine Nouguier-Soulé
SGSophie Guillon
Sophie Guillon
NANoël Amouroux
Noël Amouroux
CCClaudine Cabot
Claudine Cabot
Background: Amatoxin poisoning is a medical emergency characterized by a long incubation time lag, gastrointestinal and hepatotoxic phases, coma, and death. This mushroom intoxication is ascribed t...

1 September 2013 in Fungal Diversity
Verified
Journal Article
Closed access
PDF file
DSDilani D. De Silva
Dilani D. De Silva
SRSylvie Rapior
Sylvie Rapior
ESEnge Sudarman
Enge Sudarman
Marc StadlerMarc Stadler
Marc Stadler
JXJian-Chu Xu
Jian-Chu Xu
KHKevin D. Hyde
Kevin D. Hyde
Exploration of natural sources for novel bioactive compounds has been an emerging field of medicine over the past decades, providing drugs or lead compounds of considerable therapeutic potential. This research has provided exciting evidence on the isolation of microbe-derived metabolites having prospective biological activities. Mushrooms have been valued as traditional sources of natural bioactive compounds for many centuries and have been targeted as promising therapeutic agents. Many novel biologically active compounds have been reported as a result of research on medicinal mushrooms. In this review, we compile the information on bioactive structure-elucidated metabolites from macrofungi discovered over the last decade and highlight their unique chemical diversity and potential benefits to novel drug discovery. The main emphasis is on their anti-Alzheimer, anti-diabetic, anti-malarial, anti-microbial, anti-oxidant, anti-tumor, anti-viral and hypocholesterolemic activities which are important medicinal targets in terms of drug discovery today. Moreover, the reader’s attention is brought to focus on mushroom products and food supplements available in the market with claimed biological activities and potential human health benefits.

4 September 2012 in Fungal Diversity
Verified
Journal Article
Closed access
PDF file
DSDilani D. De Silva
Dilani D. De Silva
SRSylvie Rapior
Sylvie Rapior
KHKevin D. Hyde
Kevin D. Hyde
ABAli Bahkali
Ali Bahkali
Diabetes mellitus is a life-threatening chronic metabolic disease caused by lack of insulin and/or insulin dysfunction, characterized by high levels of glucose in the blood (hyperglycemia). Millions worldwide suffer from diabetes and its complications. Significantly, it has been recognized that type 2 diabetes is an important preventable disease and can be avoided or delayed by lifestyle intervention. Presently, there are many chemical and biochemical hypoglycemic agents (synthetic drugs), that are used in treating diabetes and are effective in controlling hyperglycemia. However, as they may have harmful side-effects and fail to significantly alter the course of diabetic complications, natural anti-diabetic drugs from medicinal plants have attracted a great deal of attention. Medicinal mushrooms have been valued as a traditional source of natural bioactive compounds over many centuries and have been targeted as potential hypoglycemic and anti-diabetic agents. Bioactive metabolites including polysaccharides, proteins, dietary fibres, and many other biomolecules isolated from medicinal mushrooms and their cultured mycelia have been shown to be successful in diabetes treatment as biological anti-hyperglycemic agents. In this review we discuss the biological nature of diabetes and, in particular, explore some promising mushrooms that have experimental anti-diabetic properties, preventing or reducing the development of diabetes mellitus. The importance of medicinal mushrooms as agents of medical nutrition therapy and how their metabolites can be used as supportive candidates for prevention and control of diabetes is explored. Future prospects for this field of study and the difficulties and constraints that might affect the development of rational drug products from medicinal mushrooms are discussed.

16 September 2015 in Mycological Progress
Verified
Journal Article
Closed access
PDF file
BTBenjarong Thongbai
Benjarong Thongbai
SRSylvie Rapior
Sylvie Rapior
KHKevin D. Hyde
Kevin D. Hyde
KWKathrin Wittstein
Kathrin Wittstein
Marc StadlerMarc Stadler
Marc Stadler

19 May 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Allen Grace NiegoAllen Grace Niego
Allen Grace Niego
SRSylvie Rapior
Sylvie Rapior
Naritsada ThongklangNaritsada Thongklang
Naritsada Thongklang
OROlivier Raspé
Olivier Raspé
WJWuttichai Jaidee
Wuttichai Jaidee
KHKevin D. Hyde
Kevin D. Hyde
Macrofungi production and economic value have been increasing globally. The demand for macrofungi has expanded rapidly owing to their popularity among consumers, pleasant taste, and unique flavors. The presence of high quality proteins, polysaccharides, unsaturated fatty acids, minerals, triterpene sterols, and secondary metabolites makes macrofungi an important commodity. Macrofungi are well known for their ability to protect from or cure various health problems, such as immunodeficiency, cancer, inflammation, hypertension, hyperlipidemia, hypercholesterolemia, and obesity. Many studies have demonstrated their medicinal properties, supported by both in vivo and in vitro experimental studies, as well as clinical trials. Numerous bioactive compounds isolated from mushrooms, such as polysaccharides, proteins, fats, phenolic compounds, and vitamins, possess strong bioactivities. Consequently, they can be considered as an important source of nutraceuticals. Numerous edible mushrooms have been studied for their bioactivities, but only a few species have made it to the market. Many species remain to be explored. The converging trends and popularity of eastern herbal medicines, natural/organic food product preference, gut-healthy products, and positive outlook towards sports nutrition are supporting the growth in the medicinal mushroom market. The consumption of medicinal mushrooms as functional food or dietary supplement is expected to markedly increase in the future. The global medicinal mushroom market size is projected to increase by USD 13.88 billion from 2018 to 2022. The global market values of promising bioactive compounds, such as lentinan and lovastatin, are also expected to rise. With such a market growth, mushroom nutraceuticals hold to be very promising in the years to come.